Choice of Anticoagulant for Primary Hemostasis Studies with PFA200® (Platelet Function Analyser)

Last updated: January 21, 2025
Sponsor: Centre Hospitalier Universitaire Dijon
Overall Status: Active - Recruiting

Phase

N/A

Condition

Blood Clots

Treatment

Sampling of 3 additional BAPA tubes

Clinical Study ID

NCT06753838
DE MAISTRE 2024
  • Ages > 18
  • All Genders

Study Summary

The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction. It is performed using citrated blood, with technical difficulties and frequent alarms that may be linked to the choice of anticoagulant (citrate). It is proposed to compare the results obtained with a conventional citrate tube and a BAPA tube, which is an anticoagulant used in clinical research and which blocks coagulation by another mechanism that would have less impact on blood platelets.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Person having given their non-opposition

  • Person of legal age

  • Person receiving a haemostasis consultation at the haemophilia and haemorrhagicdiseases treatment center followed by a blood sample with a PFA test prescribed bythe doctor (the test is not added for the study).

Exclusion

Exclusion Criteria:

  • persons under legal protection (curatorship, guardianship)

  • persons subject to a court protection order

  • pregnant, parturient or breast-feeding women

  • adult incapable or unable to give consent

  • minor

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Sampling of 3 additional BAPA tubes
Phase:
Study Start date:
January 21, 2025
Estimated Completion Date:
August 31, 2025

Connect with a study center

  • CHU Dijon Bourgogne

    Dijon, 21000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.